Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for atogepant (Qulipta) for the prevention of chronic migraine in adults with at least 15 headache days per month (among which 8 days are considered to be migraine days) and who have previously failed, are intolerant to, or have a contraindication to at least two migraine preventive therapies.